Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
10612studies shown
Showing 2,077-2,088 of 10,612
Drug study icon
CompletedNCT01714713

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

In United States
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
United States, Australia, Canada, ...
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Drug study icon
CompletedNCT02059642

MG01CI 1400 mg Compared With Placebo for ADHD

This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.

In United States
ADHDDrugFrom 18 Years to 55 Years
Countries
United States, Israel
Sponsor
Alcobra Ltd.
Condition
ADHD
Drug study icon
CompletedEUCTR 2013-001695-38

A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United States
SchizophreniaDrugFrom 13 Years to 17 Years
Countries
United States, France, United Kingdom, ...
Sponsor
SUNOVION PHARMACEUTICALS INC.
Condition
Schizophrenia
Drug study icon
CompletedNCT05024747

21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) for Addiction

This study is completed in the United States. It is testing 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) for Addiction.

In United States
AddictionDrugFrom 21 Years to 55 Years
Countries
United States
Sponsor
HALEON
Condition
Addiction
Drug study icon
CompletedNCT05113771

Liafensine for Depression

This study is completed in the United States and in Canada. It is testing liafensine for Depression.

In United States
DepressionDrugFrom 18 Years to 70 Years
Countries
United States, Canada
Sponsor
Denovo Biopharma LLC
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.